AG˹ٷ

STOCK TITAN

[8-K] Intensity Therapeutics, Inc. Common stock Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Impinj, Inc. (PI) Form 144 filing reveals an unidentified insider’s plan to sell 12,344 common shares through Charles Schwab, representing an aggregate market value of $1.98 million. The sale is slated for 08 Aug 2025 on the NASDAQ.

The shares were obtained the same day via an employee stock-option exercise. With 29.1 million shares outstanding, the proposed sale equals roughly 0.04 % of total float—too small to materially affect supply. No other insider sales occurred in the past three months, and the filer certifies awareness of no undisclosed adverse information.

Impinj, Inc. (PI) comunicazione Form 144 rivela l'intenzione di un insider non identificato di vendere 12.344 azioni ordinarie tramite Charles Schwab, per un valore di mercato complessivo di 1,98 milioni di dollari. La vendita è prevista per il 08 agosto 2025 sul NASDAQ.

Le azioni sono state ottenute lo stesso giorno attraverso un esercizio di opzioni su azioni per dipendenti. Con 29,1 milioni di azioni in circolazione, la vendita proposta rappresenta circa lo 0,04% del flottante totale, una quantità troppo ridotta per influenzare significativamente l'offerta. Negli ultimi tre mesi non si sono verificate altre vendite da parte di insider, e il dichiarante conferma di non essere a conoscenza di informazioni avverse non divulgate.

Impinj, Inc. (PI) presentación del Formulario 144 revela el plan de un insider no identificado para vender 12,344 acciones comunes a través de Charles Schwab, con un valor de mercado total de 1,98 millones de dólares. La venta está programada para el 08 de agosto de 2025 en el NASDAQ.

Las acciones fueron adquiridas el mismo día mediante un ejercicio de opciones sobre acciones para empleados. Con 29,1 millones de acciones en circulación, la venta propuesta representa aproximadamente el 0,04 % del flotante total, demasiado pequeña para afectar materialmente la oferta. No se han producido otras ventas de insiders en los últimos tres meses, y el declarante certifica no tener conocimiento de información adversa no divulgada.

Impinj, Inc. (PI) Form 144 제출은 식별되지 않은 내부자가 Charles Schwab� 통해 12,344 보통�� 판매� 계획임을 보여주며, 이는 � 시장 가� 198� 달러� 해당합니�. 판매� 2025� 8� 8� NASDAQ에서 예정되어 있습니다.

� 주식들은 같은 � 직원 주식 옵션 행사� 통해 취득되었습니�. 2,910� 주의 유통 주식� 비교� �, 제안� 판매량은 � 유동 주식� � 0.04%� 불과하여 공급� 실질적인 영향� 미치기에� 너무 적습니다. 지� 3개월 동안 다른 내부� 판매� 없었으며, 제출자는 공개되지 않은 불리� 정보가 없음� 확인합니�.

Impinj, Inc. (PI) dépôt du formulaire 144 révèle le projet d’un initié non identifié de vendre 12 344 actions ordinaires via Charles Schwab, représentant une valeur marchande totale de 1,98 million de dollars. La vente est prévue pour le 8 août 2025 sur le NASDAQ.

Les actions ont été acquises le même jour par l’exercice d�options d’achat d’actions pour employés. Avec 29,1 millions d’actions en circulation, la vente proposée représente environ 0,04 % du flottant total, une quantité trop faible pour affecter significativement l’offre. Aucun autre insider n’a vendu au cours des trois derniers mois, et le déclarant certifie ne pas avoir connaissance d’informations défavorables non divulguées.

Impinj, Inc. (PI) Form 144 Einreichung zeigt den Plan eines nicht identifizierten Insiders, 12.344 Stammaktien über Charles Schwab zu verkaufen, was einem Gesamtmarktwert von 1,98 Millionen US-Dollar entspricht. Der Verkauf ist für den 08. August 2025 an der NASDAQ geplant.

Die Aktien wurden am selben Tag durch die Ausübung von Mitarbeiteraktienoptionen erworben. Bei 29,1 Millionen ausstehenden Aktien entspricht der geplante Verkauf etwa 0,04 % des Gesamtbestands � zu gering, um das Angebot wesentlich zu beeinflussen. In den letzten drei Monaten gab es keine weiteren Insiderverkäufe, und der Einreicher bestätigt, keine nicht offengelegten negativen Informationen zu kennen.

Positive
  • None.
Negative
  • Insider intends to sell 12,344 shares (~$1.98 M), a potential—though minor—signal of profit-taking.

Insights

TL;DR: Small insider sale (~$2 M, 0.04 % of float); limited market impact but may hint at routine profit-taking.

The Form 144 discloses a modest disposition of 12,344 shares by an Impinj insider following an option exercise. At 0.04 % of outstanding shares, liquidity impact is negligible and unlikely to pressure the stock price. The absence of other recent sales and the standard representation of no undisclosed adverse information suggest this is a routine transaction rather than a bearish signal. Investors may monitor further filings for patterns, but on its own the event is neutral to valuation.

Impinj, Inc. (PI) comunicazione Form 144 rivela l'intenzione di un insider non identificato di vendere 12.344 azioni ordinarie tramite Charles Schwab, per un valore di mercato complessivo di 1,98 milioni di dollari. La vendita è prevista per il 08 agosto 2025 sul NASDAQ.

Le azioni sono state ottenute lo stesso giorno attraverso un esercizio di opzioni su azioni per dipendenti. Con 29,1 milioni di azioni in circolazione, la vendita proposta rappresenta circa lo 0,04% del flottante totale, una quantità troppo ridotta per influenzare significativamente l'offerta. Negli ultimi tre mesi non si sono verificate altre vendite da parte di insider, e il dichiarante conferma di non essere a conoscenza di informazioni avverse non divulgate.

Impinj, Inc. (PI) presentación del Formulario 144 revela el plan de un insider no identificado para vender 12,344 acciones comunes a través de Charles Schwab, con un valor de mercado total de 1,98 millones de dólares. La venta está programada para el 08 de agosto de 2025 en el NASDAQ.

Las acciones fueron adquiridas el mismo día mediante un ejercicio de opciones sobre acciones para empleados. Con 29,1 millones de acciones en circulación, la venta propuesta representa aproximadamente el 0,04 % del flotante total, demasiado pequeña para afectar materialmente la oferta. No se han producido otras ventas de insiders en los últimos tres meses, y el declarante certifica no tener conocimiento de información adversa no divulgada.

Impinj, Inc. (PI) Form 144 제출은 식별되지 않은 내부자가 Charles Schwab� 통해 12,344 보통�� 판매� 계획임을 보여주며, 이는 � 시장 가� 198� 달러� 해당합니�. 판매� 2025� 8� 8� NASDAQ에서 예정되어 있습니다.

� 주식들은 같은 � 직원 주식 옵션 행사� 통해 취득되었습니�. 2,910� 주의 유통 주식� 비교� �, 제안� 판매량은 � 유동 주식� � 0.04%� 불과하여 공급� 실질적인 영향� 미치기에� 너무 적습니다. 지� 3개월 동안 다른 내부� 판매� 없었으며, 제출자는 공개되지 않은 불리� 정보가 없음� 확인합니�.

Impinj, Inc. (PI) dépôt du formulaire 144 révèle le projet d’un initié non identifié de vendre 12 344 actions ordinaires via Charles Schwab, représentant une valeur marchande totale de 1,98 million de dollars. La vente est prévue pour le 8 août 2025 sur le NASDAQ.

Les actions ont été acquises le même jour par l’exercice d�options d’achat d’actions pour employés. Avec 29,1 millions d’actions en circulation, la vente proposée représente environ 0,04 % du flottant total, une quantité trop faible pour affecter significativement l’offre. Aucun autre insider n’a vendu au cours des trois derniers mois, et le déclarant certifie ne pas avoir connaissance d’informations défavorables non divulguées.

Impinj, Inc. (PI) Form 144 Einreichung zeigt den Plan eines nicht identifizierten Insiders, 12.344 Stammaktien über Charles Schwab zu verkaufen, was einem Gesamtmarktwert von 1,98 Millionen US-Dollar entspricht. Der Verkauf ist für den 08. August 2025 an der NASDAQ geplant.

Die Aktien wurden am selben Tag durch die Ausübung von Mitarbeiteraktienoptionen erworben. Bei 29,1 Millionen ausstehenden Aktien entspricht der geplante Verkauf etwa 0,04 % des Gesamtbestands � zu gering, um das Angebot wesentlich zu beeinflussen. In den letzten drei Monaten gab es keine weiteren Insiderverkäufe, und der Einreicher bestätigt, keine nicht offengelegten negativen Informationen zu kennen.

0001567264FALSE00015672642025-08-042025-08-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 4, 2025
Intensity Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware001-4110946-1488089
(State or Other Jurisdiction
of Incorporation)
(Commission File Number) (IRS Employer
Identification No.)
1 Enterprise Drive, Suite 430
Shelton, CT
06484-4779
(Address of Principal Executive Offices)(Zip Code)
(203) 221-7381
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class:Trading Symbol(s):Name of Exchange on Which Registered:
Common Stock, $0.0001 par value per shareINTSThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 8.01. Other Events.

On August 4, 2025, Intensity Therapeutics, Inc. (the “Company”) announced that it raised approximately $6.6 million in July 2025 from the sale of shares of common stock pursuant to its previously announced At-the-Market offering. Following such sales of common stock, the Company has 46,035,081 shares of common stock issued and outstanding as of July 31, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1
Press Release issued August 4, 2025.
104Cover Page Interactive Data File (formatted in Inline XBRL).

1


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 4, 2025
Intensity Therapeutics, Inc.
By:/s/ Lewis H. Bender
Name: Lewis H. Bender
Title:Chief Executive Officer

2

FAQ

How many Impinj (PI) shares are being sold under this Form 144?

The filing covers 12,344 common shares.

What is the market value of the proposed Impinj share sale?

The shares are valued at approximately $1.98 million.

When is the insider sale expected to occur?

The approximate sale date is 08/04/2025.

How large is the sale relative to Impinj’s total shares outstanding?

It equals about 0.04 % of the 29.1 million shares currently outstanding.

How were the shares being sold acquired?

They were obtained through an employee stock-option exercise on the same date as the planned sale.
INTENSITY THERAPEUTICS INC

NASDAQ:INTS

INTS Rankings

INTS Latest News

INTS Latest SEC Filings

INTS Stock Data

7.64M
19.84M
23.91%
10.08%
1.49%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SHELTON